

---

**UNAUDITED FINANCIAL STATEMENTS ANNOUNCEMENT FOR THE HALF YEAR ENDED 30 JUNE (“HY”) 2020**

---

This announcement has been reviewed by the Company’s sponsor, SAC Capital Private Limited (the “**Sponsor**”). This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited (the “**SGX-ST**”) and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made, or reports contained in this announcement.

The contact person for the Sponsor is Ms Lee Khai Yinn, telephone: (65) 6232 3210, 1 Robinson Road, #21-00 AIA Tower, Singapore 048542.

HEALTHBANK HOLDINGS LIMITED  
(Company Registration No.: 201334844E)

**PART I - INFORMATION REQUIRED FOR ANNOUNCEMENTS OF QUARTERLY (Q1, Q2 & Q3), HALF YEAR AND FULL YEAR RESULTS**

**1(a)(i) An income statement and statement of comprehensive income (for the group), together with a comparative statement for the corresponding period of the immediately preceding financial year.**

**CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME**

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME	The Group		Change %
	RMB'000		
	HY2020	HY2019	
Revenue	195	2,376	(92)
Other income	93	1	>100
Other gains - net	9	3,269	NM
Expected credit loss allowance on trade receivables	(2,462)	(566)	>100
Impairment loss on intangible assets	(10,326)	-	NM
Amortisation of intangible assets	(518)	(512)	1
Amortisation of right-of-use asset	-	(493)	NM
Depreciation of property, plant and equipment	(12)	(15)	(20)
Employee compensation	(875)	(4,123)	(79)
Other expenses	(694)	(1,033)	(33)
Total expenses	(14,887)	(6,742)	>100
Loss before income tax	(14,590)	(1,096)	>100
Income tax credit/(expense)	3,528	(61)	NM
Loss for the financial period	(11,062)	(1,157)	>100
Other comprehensive loss			
Items that may be reclassified subsequently to profit or loss:			
Currency translation differences arising from consolidation	(138)	114	NM
Other comprehensive (loss)/gain, net of tax	(138)	114	NM
Total comprehensive loss for the financial period	(11,200)	(1,043)	>100
Loss attributable to:			
Equity holders of the Company	(9,703)	(253)	>100
Non-controlling interests	(1,359)	(904)	50
	(11,062)	(1,157)	>100
Total comprehensive loss attributable to:			
Equity holders of the Company	(9,841)	(139)	>100
Non-controlling interests	(1,359)	(904)	50
	(11,200)	(1,043)	>100

NM – Not Meaningful

**1(a)(ii) Additional information for the income statement**

The Group's loss for the financial period is derived at after charging/(crediting):

	The Group		
	HY2020	HY2019	Change
	RMB'000	RMB'000	%
Interest income – bank deposits	-	(1)	NM
Fair value gain on financial assets, at fair value through profit or loss ("FVTPL")	-	(1,414)	NM
Currency exchange (gains)/losses – net	(9)	114	NM
Gain on disposal of a subsidiary corporation	-	(1,964)	NM

NM – Not Meaningful

HEALTHBANK HOLDINGS LIMITED  
(Company Registration No.: 201334844E)

**1(b)(i) A statement of financial position (for the issuer and group), together with a comparative statement as at the end of the immediately preceding financial year.**

**BALANCE SHEETS**

**ASSETS**

**Current assets**

Cash and bank balances

Trade and other receivables

**Non-current assets**

Financial assets, at FVTPL

Property, plant and equipment

Intangible assets

Investments in subsidiary corporations

Other receivables

**Total assets**

**LIABILITIES**

**Current liabilities**

Trade and other payables

Current income tax liabilities

**Non-current liabilities**

Deferred income tax liabilities

**Total liabilities**

**NET ASSETS**

**EQUITY**

**Capital and reserves attributable to equity holders of the Company**

Share capital

Currency translation reserves

Accumulated profits

Non-controlling interests

**Total equity**

	Group		Company	
	30 Jun 20 RMB'000	31 Dec 19 RMB'000	30 Jun 20 RMB'000	31 Dec 19 RMB'000
	2,331	9,715	83	4
	1,393	3,754	16,669	33,319
	3,724	13,469	16,752	33,323
	55,227	55,227	-	-
	126	147	120	134
	-	10,844	-	-
	-	-	39,600	39,600
	14,000	8,500	-	-
	69,353	74,718	39,720	39,734
	73,077	88,187	56,472	73,057
	3,484	3,865	528	625
	54	55	-	-
	3,538	3,920	528	625
	390	3,918	-	-
	390	3,918	-	-
	3,928	7,838	528	625
	69,149	80,349	55,944	72,432
	29,194	29,194	29,194	29,194
	1,605	1,743	5,262	5,979
	21,694	31,397	21,488	37,259
	52,493	62,334	55,944	72,432
	16,656	18,015	-	-
	69,149	80,349	55,944	72,432

HEALTHBANK HOLDINGS LIMITED  
(Company Registration No.: 201334844E)

**1(b)(ii) Aggregate amount of group's borrowings and debt securities as at the end of the current financial period reported on with comparative figures as at the end of the immediately preceding financial year.**

Not applicable. There were no borrowings and debt securities recorded as at 30 June 2020 and 31 December 2019.

**1(c) A cash flow statement (for the group), together with a comparative statement for the corresponding period of the immediately preceding financial year.**

**CONSOLIDATED STATEMENT OF CASH FLOWS**

	HY2020	HY2019
	RMB'000	RMB'000
<b>Cash flows (used in) operating activities:</b>		
Loss before income tax	(14,590)	(1,157)
Adjustments for:		
Depreciation of property, plant and equipment	12	15
Amortisation of intangible assets	518	512
Amortisation of right-of-use asset	-	493
Finance expenses	-	40
Interest income	-	(1)
Fair value gain on financial assets, at FVTPL	-	(1,414)
Impairment loss on intangible assets	10,326	-
Unrealised currency translation losses	(138)	114
Operating cash flows before movements in working capital	(3,872)	(1,398)
Change in working capital:		
Trade and other receivables	2,370	2,462
Trade and other payables	(382)	(3,073)
Financial assets, at FVTPL	-	1,048
Cash(used in) operations	(1,884)	(961)
Interest received	-	1
Income tax refunded	-	19
<b>Net cash (used in) operating activities</b>	<b>(1,884)</b>	<b>(941)</b>
<b>Cash flows from investing activities:</b>		
Disposal of property, plant and equipment	-	104
<b>Net cash provided by investing activities</b>	<b>-</b>	<b>104</b>
<b>Cash flows (used in) financing activities:</b>		
Repayment of lease liability	-	(533)
Loan to a related party	(5,500)	-
<b>Net cash (used in) financing activities</b>	<b>(5,500)</b>	<b>(533)</b>
<b>Net decrease in cash and bank balances</b>	<b>(7,384)</b>	<b>(1,370)</b>
<b>Cash and bank balances</b>		
Beginning of financial period	9,715	1,980
End of financial period	2,331	610

**1(d)(i) A statement (for the issuer and group) showing either (i) all changes in equity or (ii) changes in equity other than those arising from capitalisation issues and distributions to shareholders, together with a comparative statement for the corresponding period of the immediately preceding financial year.**

<b>The Group</b>	<b>Share Capital</b>	<b>Currency Translation Reserves</b>	<b>Accumulated Profits</b>	<b>Non-Controlling Interests</b>	<b>Total</b>
	<b>RMB'000</b>	<b>RMB'000</b>	<b>RMB'000</b>	<b>RMB'000</b>	<b>RMB'000</b>
At 1 January 2020	29,194	1,743	31,397	18,015	80,349
Total comprehensive loss for the financial period	-	(138)	(9,703)	(1,359)	(11,200)
<b>At 30 June 2020</b>	<b>29,194</b>	<b>1,605</b>	<b>21,694</b>	<b>16,656</b>	<b>69,149</b>
At 1 January 2019	29,194	1,767	46,968	19,572	97,501
Total comprehensive income/(loss) for the financial period	-	114	(253)	(904)	(1,043)
At 30 June 2019	<b>29,194</b>	<b>1,881</b>	<b>46,715</b>	<b>18,668</b>	<b>96,458</b>

<b>The Company</b>	<b>Share Capital</b>	<b>Currency Translation Reserves</b>	<b>Accumulated Profits</b>	<b>Total</b>
	<b>RMB'000</b>	<b>RMB'000</b>	<b>RMB'000</b>	
At 1 January 2020	29,194	5,979	37,259	72,432
Total comprehensive loss for the financial period	-	(717)	(15,771)	(16,488)
<b>At 30 June 2020</b>	<b>29,194</b>	<b>5,262</b>	<b>21,488</b>	<b>55,944</b>
At 1 January 2019	29,194	3,550	42,606	75,350
Total comprehensive income/(loss) for the financial period	-	1,072	(1,675)	(603)
At 30 June 2019	29,194	4,622	40,931	74,747

HEALTHBANK HOLDINGS LIMITED  
(Company Registration No.: 201334844E)

**1(d)(ii) Details of any changes in the company's share capital arising from rights issue, bonus issue, subdivision, consolidation, share buy-backs, exercise of share options or warrants, conversion of other issues of equity securities, issue of shares for cash or as consideration for acquisition or for any other purposes since the end of the previous period reported on. State the number of shares that may be issued on conversion of all the outstanding convertibles, if any, against the total number of issued shares excluding treasury shares and subsidiary holdings of the issuer, as at the end of the current financial period reported on and as at the end of the corresponding period of the immediately preceding financial year. State also the number of shares held as treasury shares and the number of subsidiary holdings, if any, and the percentage of the aggregate number of treasury shares and subsidiary holdings held against the total number of shares outstanding in a class that is listed as at the end of the current financial period reported on and as at the end of the corresponding period of the immediately preceding financial year.**

Ordinary shares of the Company	Number of shares	Share capital RMB
	78,000,000	29,194,031
As at 30 June 2020 and 31 December 2019		

The Company did not have any outstanding options, convertibles, treasury shares and subsidiary holdings as at 30 June 2020 and 30 June 2019.

**1(d)(iii) To show the total number of issued shares excluding treasury shares as at the end of the current financial period and as at the end of the immediately preceding year.**

The Company's total number of issued shares (excluding treasury shares) as at 30 June 2020 was 78,000,000 ordinary shares (31 December 2019: 78,000,000 ordinary shares).

There were no treasury shares as at the end of the current financial period and as at the end of the immediately preceding financial year.

**1(d)(iv) A statement showing all sales, transfers, cancellation and/or use of treasury shares as at the end of the current financial period reported on.**

There were no sales, transfers, cancellation and/or use of treasury shares during HY2020.

**1(d)(v) A statement showing all sales, transfers, cancellation and/or use of subsidiary holdings as at the end of the current financial period reported on.**

There were no sales, transfers, cancellation and/or use of subsidiary holdings during HY2020.

**2. Whether the figures have been audited or reviewed, and in accordance with which auditing standard or practice.**

The figures have not been audited or reviewed by the auditors of the Company.

**3. Where the figures have been audited or reviewed, the auditors' report (including any modifications or emphasis of a matter).**

Not applicable.

HEALTHBANK HOLDINGS LIMITED  
(Company Registration No.: 201334844E)

**3A. Where the latest financial statements are subject to an adverse opinion, qualified opinion or disclaimer of opinion:**

**(a) Updates on the efforts taken to resolve each outstanding audit issue.**

**(b) Confirmation from the Board that the impact of all outstanding audit issues on the financial statements have been adequately disclosed.**

**This is not required for any audit issue that is a material uncertainty relating to going concern.**

Not applicable. The Group's latest audited financial statements for the financial year ended 31 December 2019 were not subject to an adverse opinion, qualified opinion or disclaimer of opinion.

**4. Whether the same accounting policies and methods of computation as in the issuer's most recently audited annual financial statements have been applied.**

Save as disclosed in Paragraph 5 below, the Group has applied the same accounting policies and methods of computation in the Group's financial statements for HY2020 compared to the audited financial statements for FY2019.

**5. If there are any changes in the accounting policies and methods of computation, including any required by an accounting standard, what has changed, as well as the reasons for, and the effect of, the change.**

The Group has adopted all new and revised SFRS(I) and Interpretations of SFRS(I) that are relevant to its operations and effective for the financial period on or after 1 January 2020, where applicable. The adoption of these new and revised standards from the effective date did not result in significant change to the Group's accounting policies and did not have a material impact on the Group's results for HY2020.

**6. Earnings per ordinary share of the group for the current financial period reported on and the corresponding period of the immediately preceding financial year, after deducting any provision for preference dividends.**

Loss per share ("LPS")	The Group	
	HY2020	HY2019
Loss for the financial period attributable to equity holders of the Company (RMB'000)	<b>(9,703)</b>	(253)
Weighted average number of ordinary shares outstanding for basic and diluted LPS ('000)	<b>78,000</b>	78,000
<b>Basic and diluted LPS (RMB cents) <sup>(1)</sup></b>	<b>(12.44)</b>	(0.32)

<sup>(1)</sup> The basic and diluted EPS were the same as the Company and the Group did not have any potentially dilutive instruments for the respective financial periods.



HEALTHBANK HOLDINGS LIMITED  
(Company Registration No.: 201334844E)

7. **Net asset value (for the issuer and group) per ordinary share based on the total number of issued shares excluding treasury shares of the issuer at the end of the:**
- (a) **current financial period reported on; and**  
(b) **immediately preceding financial year.**

	Group		Company	
<b>Net asset value (“NAV”) per ordinary share</b>	<b>30 Jun 20</b>	<b>31 Dec 19</b>	<b>30 Jun 20</b>	<b>31 Dec 19</b>
NAV attributable to equity holders of the Company (RMB’000)	<b>52,493</b>	62,334	<b>55,944</b>	72,432
Number of ordinary shares (’000)	<b>78,000</b>	78,000	<b>78,000</b>	78,000
NAV per ordinary share based on issued share capital (RMB)	<b>0.67</b>	0.80	<b>0.72</b>	0.93

8. **A review of the performance of the group, to the extent necessary for a reasonable understanding of the group’s business. It must include a discussion of the following:**

- (a) **any significant factors that affected the turnover, costs, and earnings of the group for the current financial period reported on, including (where applicable) seasonal or cyclical factors; and**  
(b) **any material factors that affected the cash flow, working capital, assets or liabilities of the group during the current financial period reported on.**

#### **REVIEW OF FINANCIAL PERFORMANCE**

As at 30 June 2020, the Group hospitality division has five hotels under long-term management contracts in People’s Republic of China (“China”). Three of these hotels were in operation during HY2020 and the details are as follows:

<b>Names of hotels/resorts</b>	<b>Number of rooms</b>	<b>Location</b>
Libre Resorts Huangshan	528	Huangshan, Anhui Province, China <sup>(1)(2)</sup>
Libre Resorts Lijiang	562	Lijiang, Yunnan Province, China <sup>(1)(3)</sup>
Libre Collection Yizheng	36	Yangzhou, Jiangsu Province, China <sup>(1)(4)(5)</sup>

#### **Notes:**

- (1) In view of the recent COVID-19 outbreak, these hotels were temporarily closed under the directives from the Chinese government and local health authorities since 24 January 2020.  
(2) Libre Resorts Huangshan has resumed operation on 20 April 2020.  
(3) Libre Resorts Lijiang has resumed operation on 1 May 2020.  
(4) Libre Collection Yizheng has resumed operation on 15 May 2020.  
(5) The hotel management company, Yangzhou Asset Management Co., Ltd is undergoing restructuring and has dispute with the hotel owner, the Group did not recognize revenue on a prudence basis. In any case, the revenue contribution from this hotel is not expected to be material to the Group.

#### **Revenue**

The Group achieved revenue of RMB 0.20 million in HY2020 compared to RMB 2.38 million in HY2019, all of which are pertaining to hotel management fees. The Group’s hospitality business in China have been adversely impacted by the COVID-19 pandemic. This has resulted in lower revenue from the hospitality facilities management services due to severe restrictive business operations and movement control for local and international travelers since January 2020.

**Other income**

The Group's other income in HY2020 was mostly from the Job Support Scheme ("JSS") received, a financial support scheme by the Singapore Government to provide wage supports to employers, helping enterprises retain their local employees during this period of economic uncertainty due to COVID-19 pandemic.

**Other gains**

The Group's other gains in HY2020 was mainly contributed by foreign exchange gains. In HY2019, the Group's other gains was mainly contributed by the fair value gain of financial assets, at FVTPL and gain on disposal of a subsidiary.

**Expected credit loss allowance on trade receivables**

The Group has provided in full expected credit loss for long outstanding trade receivables of more than 1 year and 50% expected credit loss for long outstanding trade receivables of more than 180 days but less than 1 year which amounted to RMB 2.46 million due to slow collection of trade receivables as customers' liquidity and credit access continue to deteriorate as a result of the impact arising from the COVID-19 outbreak, the slowing Chinese economy as well as the legacy of previous deleveraging policy introduced by the Chinese Government.

**Impairment loss on intangible assets**

Impairment loss on intangible assets of RMB 10.33 million which arose from the acquisition of Beijing Shengting Commercial Management Co., Ltd ("BJST") was provided due to weak forward-looking outlook and uncertainties arising from the COVID-19 pandemic and continuing US-China trade tensions.

The impairment of intangible assets was assessed in accordance to SFRS (I) 1-36 – Impairment of Assets whereby the carrying amount of intangible assets are compared to the recoverable amount, which is the higher of value-in-use and the fair value less costs to sell. The management has applied value-in-use model by computing sales and cashflow projection, as well as applying appropriate discount rate to determine the recoverable amount. An impairment loss was recognised as the carrying amount exceeded the recoverable amount.

**Amortisation of intangible assets and right-of-use assets**

The Group's amortisation of intangible assets of RMB 0.52 million in HY2020 arose from the acquisition of BJST. The Group amortises the intangible assets over a span of 12 to 15 years in accordance to the contract periods of the management contracts and naming rights.

There was no amortisation of right-of-use asset recorded in HY2020 due to the termination of office lease as a result of staff streamlining of China team as part of the Group's cost management measures. The China team is currently utilising a business associate's working space due to small headcounts.

**Employee compensation**

The employee compensation decreased by RMB 3.25 million or 79%, from RMB 4.12 million in HY2019 to RMB 0.87 million in HY2020, due to smaller headcounts and various cost management measures including staff streamlining and performance-based reward system for the China team to improve the profitability of the Group.

**Other expenses**

The decrease in other expenses of RMB 0.34 million or 33% was mainly due to reduction in rental expenses of RMB 0.28 million, from RMB 0.28 million in HY2019 to NIL in HY2020, as the China team is currently utilizing a business associate's working space due to smaller headcounts.

**Income tax credit**

The Group recorded a loss before tax of RMB 14.59 million and income tax is not provided for the reporting period. The Group de-recognized deferred tax liability of RMB 3.53 million following the full impairment of intangible assets in HY2020 which was previously allocated with deferred tax liability based on the statutory tax applied on the fair value of the intangible assets.

**Loss for the financial period**

The Group recorded a loss after tax of RMB 11.06 million in HY2020 as compared to a loss after tax of RMB 1.16 million in HY2019 mainly as a result of impairment of intangible assets, expected credit loss allowance on trade receivables, and lower revenue achieved due to severe impact of COVID-19 pandemic offset by de-recognised of deferred tax liability.

**Non-controlling interests**

The loss attributable to non-controlling interests amounted to RMB 1.36 million for HY2020 as compared to a loss of RMB 0.90 million in HY2019.

**REVIEW OF FINANCIAL POSITION****Current assets**

Cash and bank balances decreased by RMB 7.38 million, from RMB 9.71 million as at 31 December 2019 to RMB 2.33 million as at 30 June 2020. Please refer to the "Review of Cash Position" section below for further details on the material cash movements.

As at 30 June 2020, the Group has trade receivables amounting to RMB 0.72 million which comprises of hotel management fees revenue due from customers. The decrease of RMB 2.40 million in trade receivables, from RMB 3.12 million was mainly due to expected credit loss allowance.

As at 30 June 2020, the Group has other receivables of RMB 0.67 million, increased slightly from RMB 0.64 million as at 31 December 2019.

**Non-current assets**

Intangible assets comprising of management contracts and naming rights from the acquisition of BJST of RMB 10.33 million as at 30 June 2020 was fully impaired in accordance with SFRS (I)1-36 – Impairment of Assets as the recoverable amount is lower than the carrying amount.

Other receivables increased by RMB 5.50 million, from RMB 8.50 million to RMB14.0 million, due to loan to related party for Atlantis Garden Project.

**Current liabilities**

The Group's trade and other payables decreased by RMB 0.38 million, from RMB 3.86 million as at 31 December 2019 to RMB 3.48 million as at 30 June 2020, mainly due to payments made and lower accrued operating expenses.

**Non-current liabilities**

The Group's non-current liabilities mainly comprises deferred income tax liabilities of RMB 0.39 million as at 30 June 2020, pertaining to provision for deferred tax liabilities on unremitted earnings from foreign subsidiaries in accordance with SFRS (I) 1-12 Income Taxes. The reduction of RMB 3.53 million from RMB 3.92 million as at 31 December 2019 was due to de-recognition of deferred tax liability following the full impairment of intangible assets in HY2020 which was previously allocated with deferred tax liability based on the statutory tax applied on the fair value of the intangible assets.

**Net current assets**

Net current assets of the Group decreased by RMB 9.36 million to RMB 0.19 million as at 30 June 2020, from RMB 9.55 million as at 31 December 2019, due mainly to expected credit loss allowance on trade receivables of RMB 2.46 million and loan to related party of RMB 5.50 million.

The Group has sufficient internal resources to fulfill its working capital requirements despite current challenging environment.

**Shareholders' equity**

The Group's equity attributable to equity holders of the Company decreased by RMB 9.84 million to RMB 52.49 million as at 30 June 2020, from RMB 62.33 million as at 31 December 2019. The decrease is due to lower revenue, expected credit loss allowance on trade receivables and impairment loss on intangible assets.

**REVIEW OF CASH POSITION**

Net cash used in operating activities of the Group amounted to RMB 1.88 million for HY2020 was mainly due to operating cash outflows before movements in working capital of RMB 3.87 million, a decrease in trade and other receivables of RMB 2.37 million, a decrease in trade and other payables of RMB 0.38 million.

Net cash used in financing activities of the Group amounted to RMB 5.50 million for HY2020 was due to loan to related party.

Overall, the Group recorded a net cash decrease of RMB 7.38 million in HY2020.

The Group has cash balance of RMB 2.33 million as at 30 June 2020.

**9. Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results.**

The Group's results for HY2020 are generally in line with the Company's profit guidance announcement dated 4 August 2020.

**10. A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the group operates and any known factors or events that may affect the group in the next reporting period and the next 12 months.**

The Group's hospitality business in China are severely affected by the COVID-19 pandemic due to restricted operation of non-essential businesses and movement control for local and international travelers since January 2020, which leads to China economy coming to a standstill, significantly affecting hospitality industry and hotel occupancy rates that lead to lower revenue recorded.

With the COVID-19 pandemic and continuing trade tensions between the United States and China, the global economic outlook and hospitality industry outlook remain no visibility certainty which in turn will affect the Group's business. The cross-border travel easing measures continue to be cautious. The travel easing measures are mainly for approved essential business travel while leisure travel is almost non-existent for most of international travellers.

Hotel owners and operators' liquidity and credit access ability continue to deteriorate as a result of the impact arising from the COVID-19 outbreak. The slowing Chinese economy as well as the legacy of previous deleveraging policy introduced by the Chinese Government greatly affect hotels operations and the owners ability to invest in new or projects upgrading.

With the economic uncertainties and the volatile market conditions, the management have implemented various cost cutting measures to improve the profitability of the Group.

Looking ahead, the Group will continue its efforts in structural financial planning and cost efficiency, as well as focus on growth through strategic restructuring and collaborations in new business segments in the tourism and hospitality industries in China, Singapore and the region, with the goal of expanding and enhancing the performance and net asset value of the Group.

As the Chinese Government imposed strict restrictions on the operation of non-essential businesses and movement control of people to contain the spread of COVID-19 since January 2020, the Atlantis Garden Project had been suspended since January 2020 until June 2020, when it resumed its normal operation and construction work. Barring unforeseen circumstances, Phase 1 of the project, which includes the construction of 2 residential buildings, is expected to be completed in the first quarter of 2021 and the Phase 2 of the project, which includes the construction of the remaining 2 residential buildings, is expected to be completed by end of 2021.

Overall, the Group expects financial performance for the next 12 months to be adversely impacted from the pandemic, while geo-political tensions continued to pose risks and uncertainty to the already difficult hospitality industry operating landscape.

Despite the challenges, the Group has sufficient liquidity to meet its operational needs and will continue to exercise prudent balance sheet management.

**11. If a decision regarding dividend has been made: -**

**(a) Whether an interim (final) dividend has been declared (recommended); and**

No dividend is declared for the current financial period reported on.

**(b) (i) Amount per share in cents**

Not applicable.

**(ii) Previous corresponding period in cents**

No dividend is declared for the corresponding period.

- (c) Whether the dividend is before tax, net of tax or tax exempt. If before tax or net of tax, state the tax rate and the country where the dividend is derived. (If the dividend is not taxable in the hands of shareholders, this must be stated).**

Not applicable.

- (d) The date the dividend is payable.**

Not applicable.

- (e) The date on which Registrable Transfers received by the company (up to 5.00pm) will be registered before entitlements to the dividend are determined.**

Not applicable.

- 12. If no dividend has been declared/recommended, a statement to that effect and the reason(s) for the decision.**

No dividend has been declared or recommended in view of the losses incurred in HY2020.

- 13. If the Group has obtained a general mandate from shareholders for interested persons transactions ("IPT") the aggregate value of such transactions as required under Rule 920(1)(a)(ii) of the Catalist Rules. If no IPT mandate has been obtained, a statement to that effect.**

The Group has not obtained a general mandate from shareholders for IPT. There are no interested person transactions of S\$100,000 or more during the financial period under review.

- 14. Confirmation that the issuer has procured undertakings from all its directors and executive officers (in the format set out in Appendix 7H) under Rule 720(1) of the Catalist Rules.**

The Company has procured undertakings from all its directors and executive officers (in the format set out in Appendix 7H) under Rule 720(1) of the Catalist Rules.

- 15. Negative confirmation by directors pursuant to Rule 705(5) of the Catalist Rules.**

We, Peng Fei and Peng Weile, being two Directors of the Company, do hereby confirm on behalf of the Board of Directors of the Company (the "**Board**") that, to the best of the Board's knowledge, nothing has come to the attention of the Board which may render the unaudited financial statements for the half year ended 30 June 2020 to be false or misleading in any material aspect.

On behalf of the Board  
Peng Fei  
Executive Director and CEO  
14 August 2020